Copyright
©The Author(s) 2021.
World J Gastroenterol. Apr 14, 2021; 27(14): 1497-1506
Published online Apr 14, 2021. doi: 10.3748/wjg.v27.i14.1497
Published online Apr 14, 2021. doi: 10.3748/wjg.v27.i14.1497
HBeAg loss (n = 72) | HBeAg seroconversion (n = 72) | P values2 | |
Age at cessation (yr) | 31.8 ± 10.0 | 31.5 ± 11.8 | 0.873 |
Male, n (%) | 49 (68.1) | 48 (66.7) | 0.859 |
Functional cure, n (%) | 15 (20.8) | 8 (11.1) | 0.111 |
Pretreatment HBV DNA (log10 copies/mL)1 | 7.14 (6.70-7.65) | 7.00 (6.67-7.67) | 0.781 |
Pretreatment ALT1 | 151 (114-287) | 200 (117-301) | 0.394 |
Pretreatment AST1 | 102 (69 -188) | 122 (72 -204) | 0.327 |
Consolidation periods (mo)1 | 28 (21-40) | 23 (15-37) | 0.065 |
Time to HBeAg loss/conversion1 | 12 (6-25) | 15 (7-27) | 0.566 |
- Citation: Xue Y, Zhang M, Li T, Liu F, Zhang LX, Fan XP, Yang BH, Wang L. Exploration of nucleos(t)ide analogs cessation in chronic hepatitis B patients with hepatitis B e antigen loss. World J Gastroenterol 2021; 27(14): 1497-1506
- URL: https://www.wjgnet.com/1007-9327/full/v27/i14/1497.htm
- DOI: https://dx.doi.org/10.3748/wjg.v27.i14.1497